Related Experiment Videos
Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression
1Imperial Cancer Research Fund Oncology Unit, Hammersmith Hospital, London, UK.
Abstract:
Antisense oligonucleotides targeting p53 have been hailed as a potentially new technique for treating patients with cancer, and there have been encouraging reports of good patient tolerance in vivo and of antiproliferative effects in vitro. However, evidence is lacking that these oligonucleotides are acting via an antisense interaction to modulate p53 expression. We examined a phosphorothioate antisense oligonucleotide, directed against exon 10 of the TP53 gene, and a chimaeric phosphorothioate-phosphodiester oligonucleotide directed against the p53 translation initiation codon. Both failed to specifically suppress p53 protein production in a cell-free assay system or to have any effect on mutant p53 expression by human pancreatic cancer cell lines. Antiproliferative effects were apparent, especially with the phosphorothioate antisense oligonucleotide, but this was independent of the p53 status of the cells (mutant, wild-type or absent) and also occurred with the control (sense and randomised) oligonucleotides. The most dramatic antiproliferative effects were seen with the 'control' phosphorothioate oligonucleotides. These findings suggest that the antiproliferative effects of some antisense oligonucleotides may be unrelated to expression of the gene they have been designed to target.
Insights
Antisense oligonucleotides targeting p53 show antiproliferative effects in cancer cells. However, these effects are independent of p53 modulation, suggesting alternative mechanisms may be responsible for their efficacy.
Area of Science:
- Molecular Biology
- Cancer Therapeutics
- Oligonucleotide Chemistry
Background:
- Antisense oligonucleotides (ASOs) targeting p53 are explored for cancer treatment.
- In vitro antiproliferative effects and in vivo tolerance have been reported.
- Specific evidence for p53 modulation via antisense interaction is lacking.
Purpose of the Study:
- To investigate if ASOs targeting p53 specifically suppress p53 expression.
- To determine if observed antiproliferative effects are p53-dependent.
- To examine the mechanism of action for p53-targeting ASOs.
Main Methods:
- Tested phosphorothioate and chimaeric ASOs against TP53 gene.
- Assessed p53 protein suppression in cell-free and cancer cell line systems.
- Evaluated antiproliferative effects across various p53 expression statuses (mutant, wild-type, absent).
Main Results:
- Neither ASO specifically suppressed p53 protein production.
- No effect on mutant p53 expression in pancreatic cancer cell lines.
- Antiproliferative effects were observed but were independent of p53 status and occurred with control oligonucleotides.
Conclusions:
- Antiproliferative effects of some p53-targeting ASOs may not involve direct p53 modulation.
- The mechanism of action for observed effects might be p53-independent.
- Further research is needed to elucidate the true mechanisms behind ASO efficacy in cancer therapy.